Appendix 4C and Quarterly Activities Report - June 2025

Appendix 4C and Quarterly Activities Report - June 2025

Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - June 2025

Download the PDF here.

Invion Limited

Invion Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Invion Limited

Invion Limited

Keep reading...Show less

Revolutionizing Photodynamic Therapy (PDT) for cancer and infectious diseases

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

 

  On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177  

 

  On track to complete enrollment of the first cohort of Phase 1 ‘HEAT' trial of RAD202 for treatment of advanced HER2-positive solid tumors  

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart

 

  Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3  

 

  On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25  

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Invion Limited

Invion Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×